CRISPR Therapeutics AG

🇺🇸NASDAQ Global Market
Back to all articles
CRISPR Therapeutics AG stock analysis CRSP overview
Slightly Bullish +25

Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

- 📊 Analysts have issued new ratings for healthcare stocks Dexcom (DXCM), Ironwood Pharma (IRWD), and Crispr Therapeutics AG (CRSP).

- 💰 Wells Fargo analyst Larry Biegelsen maintains a Buy rating on Dexcom with a price target of $85.00.

- ⚖️ TipRanks notes that Biegelsen has an average success rate of 46.6% based on his track record.

- 📈 Dexcom currently has a Strong Buy consensus with an average price target of $80.50, representing a 33% upside.

- ⛏️ Wells Fargo analyst Mohit Bansal maintains a Hold rating on Ironwood Pharma with a price target of $5.00.

- 🚀 The analyst consensus for Ironwood Pharma is Moderate Buy with an average target of $7.50, implying 61.6% upside.

- ⬇️ Wells Fargo analyst Yanan Zhu maintains a Hold on Crispr Therapeutics AG with a price target of $75.00.

- 🌟 Zhu holds a 5-star analyst rating with an average return of 18.3% according to TipRanks data.

- 🏥 The general street consensus for Crispr Therapeutics AG is Moderate Buy with a $72.31 price target.

- 🤖 TD Cowen maintained a Hold rating on Crispr with a significantly lower price target of $45.00.

- 📉 Citi recently lowered its Dexcom price target from $84 to $79.

- 📈 Baird adjusted its Dexcom price target downward from $87 to $80.

- ⬇️ Bernstein also reduced its Dexcom price target from $83 to $77.

- 💸 The article includes various promotional links for TipRanks services and portfolio management tools.

- 🗂️ Wells Fargo analyst Larry Biegelsen covers other healthcare stocks such as Anteris and Bausch + Lomb.

- 🔬 Mohit Bansal focuses on peers like Mineralys Therapeutics, BioMarin, and Vertex Pharmaceuticals.

- 🧬 Yanan Zhu has experience covering NewAmsterdam Pharma, Atrium Therapeutics, and Iovance Biotherapeutics.

- 📰 This content is a syndicated press release that has not been reviewed or endorsed by the publication.

Bullish Signals
  • Dexcom has a Strong Buy analyst consensus with an average price target of $80.50, representing a 33.0% upside from its current trading levels.
  • TipRanks upgraded Dexcom to a Buy rating with a $73.00 price target in a report issued on April 20.
  • Ironwood Pharma trades at a significant discount to analyst expectations, with a consensus average price target of $7.50 implying a 61.6% upside from current levels.
  • The analyst covering Ironwood Pharma is a highly-rated 5-star analyst with an impressive 9.8% average return and a 56.1% success rate.
  • Crispr Therapeutics AG has a Moderate Buy consensus rating with an average price target of $72.31, indicating a 37.5% upside potential from current levels.
  • Wells Fargo analyst Yanan Zhu is a top-tier 5-star analyst with an exceptional 18.3% average return who maintains a Hold rating on Crispr Therapeutics AG.
Risk Factors
  • TD Cowen maintained a Hold rating on Crispr Therapeutics AG with a low price target of $45.00, significantly below the market's moderate buy consensus average of $72.31.
  • Wells Fargo analyst Yanan Zhu assigned a Hold rating to Crispr Therapeutics AG with a $75.00 price target, which is lower than the company's recent trading closure at $52.38 and below broader market optimism.
  • The article presents conflicting views from analysts across Dexcom, Ironwood Pharma, and Crispr Therapeutics, creating uncertainty rather than clear investment conviction for these healthcare names.
  • For Ironwood Pharma, the disparity between the analyst consensus moderate buy (61.6% upside) and TD Cowen's hold rating ($4.50 target vs current $4.67) suggests significant divergence in analyst outlooks.
Full Analysis
Healthcare sector analyst activity is the primary focus of this article, which details new ratings and price targets for three specific stocks: Dexcom (DXCM), Ironwood Pharma (IRWD), and Crispr Therapeutics AG (CRSP). The content provides specific data points regarding Wells Fargo analyst recommendations for each company. For Dexcom, Wells Fargo analyst Larry Biegelsen maintained a Buy rating with a $85 price target, noting the stock closed at $59.48; however, there is noted conflict among analysts as Dexcom recently saw price targets lowered to ranges of $77-$79 by Citi and Baird in other reports mentioned in the text, with an overall consensus of Strong Buy implying a 33% upside. For Ironwood Pharma, analyst Mohit Bansal maintained a Hold rating at $5 despite a general Moderate Buy consensus suggesting a 61.6% upside to a $7.50 price target. Regarding Crispr Therapeutics AG, Wells Fargo analyst Yanan Zhu maintained a Hold rating with a $75 price target on shares closing at $52.38, though the broader Street consensus suggests a Moderate Buy with an average price target of $72.31. The article also references conflicting analyst opinions from TD Cowen, which maintained a Hold on Crispr with a significantly lower $45 price target. The summary focuses exclusively on the financial metrics and analyst actions related to these three tickers, ignoring promotional text urging readers to unlock hedge fund data or links to other unrelated market news such as Roblox or Western Digital earnings mentioned in the footer navigation style of the source text. The article qualifies for retention because all three tickers are central subjects of the analysis provided, rather than being incidental mentions within a generic market overview.